SCHEMBL8352183

SCHEMBL8352183

Cc1cccc(OC2CCC2)c1

nearest known ligand 0.63

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.63
SLC6A4 P31645 2/20 0.63
SLC6A3 Q01959 2/20 0.63
ACHE P22303 2/20 0.50
ALDH1A1 P00352 2/20 0.46
EPHX2 P34913 1/20 0.45
HRH3 Q9Y5N1 1/20 0.44
NAAA Q02083 1/20 0.43
LMNA P02545 1/20 0.43
ACSL1 P33121 1/20 0.43
HTR2C P28335 1/20 0.41
HTR2B P41595 1/20 0.41
KDM4E B2RXH2 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HRH1 P35367 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12127337 0.96 SLC6A2 (0.63) SLC6A2SLC6A4SLC6A3ACHEALDH1A1
SCHEMBL18210780 0.94 SLC6A2 (0.61) SLC6A2SLC6A4SLC6A3ACHEALDH1A1
SCHEMBL327351 0.94 SLC6A2 (0.61) SLC6A2SLC6A4SLC6A3ACHEALDH1A1
SCHEMBL12127336 0.92 SLC6A2 (0.67) SLC6A2SLC6A4SLC6A3ACHEALDH1A1
SCHEMBL13450921 0.85 SLC6A2 (0.59) SLC6A2SLC6A4SLC6A3ACHEALDH1A1
SCHEMBL8264651 0.84 SLC6A2 (0.58) SLC6A2SLC6A4SLC6A3ACHEALDH1A1
SCHEMBL29994671 0.84 HRH1 (0.62) SLC6A2SLC6A4SLC6A3ACHENAAA
SCHEMBL8358502 0.84 HRH1 (0.62) SLC6A2SLC6A4SLC6A3ACHENAAA
SCHEMBL3121897 0.84 SLC6A2 (0.58) SLC6A2SLC6A4SLC6A3ACHEALDH1A1
SCHEMBL19872749 0.83 SLC6A4 (0.54) SLC6A2SLC6A4SLC6A3ACHEALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220162191-A1 SMALL MOLECULE MODULATORS OF IL-17 LEO PHARMA A/S (DK) 2022-05-26 US disclosed
WO-2020182666-A1 SMALL MOLECULE MODULATORS OF IL-17 LEO PHARMA A/S (DK) 2020-09-17 WO disclosed
US-20090203667-A1 PENTADIENAMIDE DERIVATIVES KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-08-13 US disclosed
EP-2050734-A1 PENTADIENAMIDE DERIVATIVE Kyowa Hakko Kirin Co., Ltd. (JP) 2009-04-22 EP disclosed
WO-2003068233-A1 NICOTINAMIDE DERIVATIVES AND A TIOTROPIUM SALT IN COMBINATION FOR THE TREATMENT OF E.G. INFLAMMATORY, ALLERGIC AND RESPIRATORY DISEASES PFIZER LIMITED (GB) 2003-08-21 WO disclosed
WO-2003068235-A1 NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS PFIZER LIMITED (GB) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203667-A1 PENTADIENAMIDE DERIVATIVES PRMT1, REN, NGLY1 SLC6A2 647/4885SLC6A4 138/4885SLC6A3 97/4885
US-20220162191-A1 SMALL MOLECULE MODULATORS OF IL-17 IL17A, IL15, IL2 SLC6A2 4426/4885SLC6A4 4486/4885SLC6A3 4609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.